BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference


11/15/2011 10:53:01 AM

SAN FRANCISCO, November 15, 2011 /PRNewswire/ --

Pieris AG presented the results of the Company's first clinical evaluation of its most advanced Anticalin®, PRS-050, an anti-VEGF targeted protein therapeutic, at the 2011 AACR-NCI-EORTC International Conference held in San Francisco, California. The dose-escalation trial investigated the recommended Phase II dose, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PRS-050 administered to patients with advanced solid tumors. PRS-050 was well-tolerated, with no maximum tolerated dose reached, while demonstrating biological activity and a complete lack of immunogenicity, supporting further evaluation in a Phase II clinical trial.

"The Phase I results not only confirm the safety and tolerability of PRS-050, but also are indicative of an attractive safety profile for Anticalins generally," said Dr. Laurent Audoly, Chief Scientific Officer for Pieris AG. "Moreover, the results of our PK/PD strategy provide human data supporting the robustness of our drug platform. The Anticalin approach, which in this case, plays on monovalent target engagement, small size and the lack of an effector function, is well-suited for a biobetter VEGF-targeted therapeutic protein approach to treat several types of cancer."

The Phase I clinical trial of PRS-050 was conducted in 26 patients with advanced solid tumors as an open-label, dose-escalating evaluation of the compound's safety, tolerability, and PK/PD profile. The protein drug exhibited a half-life of six days, there was no immunogenicity (no anti-drug antibodies) observed across all cohorts and multiple dose-dependent PD effects were obtained. PRS-050 is an anti-VEGF (Vascular Endothelial Growth Factor) 40 kD PEGylated Anticalin discovered and developed internally at the company. VEGF has a well-defined role in cancer angiogenesis, which is the mechanism by which cancer tumors increase blood vessel development at the tumor site and thereby enable further growth. The compound began the clinical trial at three different sites in Germany during the first half of 2010.

The results were presented on Sunday, November 13th, 2011 at the American Association Cancer Researchers-National Cancer Institute-European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology and Clinical Applications is taking place November 12-16, 2011 at the Moscone Center West in San Francisco, California.

Anticalins are therapeutic proteins derived from human lipocalins, rationally engineered to solve for the pharmacological and pharmaceutical limitations of both protein and non-protein based drug platforms.

About Pieris AG

Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that are safer and more effective than conventional approaches. Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical needs and expand the therapeutic potential of current targeted approaches. Pieris' pipeline ranges from its Phase I compound, PRS-050 (anti-VEGF, oncology), to multiple Anticalins in preclinical development across a range of therapeutic areas. The company has four ongoing discovery and development collaborations: Daiichi Sankyo, Takeda San Francisco, the Sanofi Group and Allergan. Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures. For more information, please visit: http://www.pieris-ag.com.

For further information, please contact:
Dr. Laurent Audoly, CSO
Pieris AG
or
Gretchen Schweitzer
+49-172-861-8540
media@pieris-ag.com

Further information is available at http://www.pieris-ag.com

Anticalin®, Anticalins® are registered trademarks of Pieris AG.


SOURCE Pieris AG


Read at BioSpace.com

Related News

Pieris
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->